C07K 2319/32
Fusions with soluble part of a cell surface receptor, "decoy receptors"
Official title: fusions with soluble part of a cell surface receptor, "decoy receptors"
C07K2319/32 (Fusions with soluble part of a cell surface receptor, "decoy receptors") appears on 723 US grants and 1,086 published applications in this corpus.
Search patents in C07K- Granted patents
- 723
- Published applications
- 1,086
- Assignees
- 495
- Inventors
- 1,837
- Latest grant
- 25 Aug 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1989 | 1 | 0 |
| 1990 | 1 | 0 |
| 1991 | 2 | 0 |
| 1992 | 7 | 0 |
| 1993 | 11 | 0 |
| 1994 | 7 | 0 |
| 1995 | 8 | 0 |
| 1996 | 17 | 0 |
| 1997 | 8 | 0 |
| 1998 | 36 | 0 |
| 1999 | 14 | 0 |
| 2000 | 15 | 0 |
| 2001 | 11 | 2 |
| 2002 | 12 | 17 |
| 2003 | 12 | 27 |
| 2004 | 4 | 16 |
| 2005 | 9 | 18 |
| 2006 | 9 | 23 |
| 2007 | 10 | 16 |
| 2008 | 19 | 11 |
| 2009 | 6 | 32 |
| 2010 | 15 | 29 |
| 2011 | 13 | 32 |
| 2012 | 17 | 30 |
| 2013 | 18 | 37 |
| 2014 | 21 | 34 |
| 2015 | 19 | 38 |
| 2016 | 17 | 47 |
| 2017 | 35 | 61 |
| 2018 | 31 | 81 |
| 2019 | 36 | 65 |
| 2020 | 57 | 73 |
| 2021 | 50 | 85 |
| 2022 | 38 | 68 |
| 2023 | 35 | 81 |
| 2024 | 34 | 73 |
| 2025 | 52 | 61 |
| 2026 | 16 | 29 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- TGF-beta RII mutant and fusion protein thereof25 Aug 2026US 12,715,904 B2Mabwell (Shanghai) Bioscience Co., Ltd.
- Angiopoietin 2, VEGF dual antagonists25 Aug 2026US 12,715,912 B2AskGene Pharma Inc.
- Methods and compositions comprising enhanced targeted immune gene therapy for the treatment of cancer18 Aug 2026US 12,708,653 B2Endeavor Health Clinical Operations
- Bifunctional antagonists of activin and tumor necrosis factor alpha and uses thereof11 Aug 2026US 12,703,742 B2
- Soluble ACE2 protein, fusion proteins thereof with an FC domain, and methods of treatment of an ACE2-related disease21 Jul 2026US 12,686,860 B2Huahui Health Ltd.
- Il-15-based molecules and methods of use thereof3 Sep 2026US 2026/0256886 A1Altor BioScience Corporation
- Novel immunoconjugates13 Aug 2026US 2026/0232829 A1Cytospire Therapeutics Limited
- Cd59 for inhibiting inflammasome activation13 Aug 2026US 2026/0232845 A1Trustees of Tufts College
- Nucleic Acids Encoding Soluble PD-1 and IL-12 and Uses Thereof13 Aug 2026US 2026/0234662 A1KaliVir Immunotherapeutics, Inc.
- Targeted protein contrast agents, methods of making, and uses thereof30 Jul 2026US 2026/0216379 A1Georgia State University Research Foundation, Inc.
Most cited
By later US patents
- Hybrid immunoglobulins817US 5,116,964 AGenentech, Inc. · 1992
- Chimeric chains for receptor-associated signal transduction pathways381US 5,359,046 ACell Genesys, Inc. · 1994
- Hybrid immunoglobulins357US 5,428,130 AGenentech, Inc. · 1995
- Chimeric receptors with 4-1BB stimulatory signaling domain329US 8,399,645 B2St. Jude Children?S Research Hospital · 2013
- Lymphocyte homing receptor/immunoglobulin fusion proteins308US 5,225,538 AGenentech, Inc. · 1993